Compare MOB & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOB | OKYO |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 87.6M |
| IPO Year | 2021 | 2021 |
| Metric | MOB | OKYO |
|---|---|---|
| Price | $4.80 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $6.33 |
| AVG Volume (30 Days) | ★ 134.4K | 63.6K |
| Earning Date | 03-23-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.33 | $1.34 |
| 52 Week High | $11.01 | $3.20 |
| Indicator | MOB | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 41.41 |
| Support Level | $4.66 | N/A |
| Resistance Level | $5.67 | $1.72 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 5.98 | 19.21 |
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.